Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...
By Sneha S K (Reuters) -Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle Group and SK Capital ...
An experimental trial of gene therapy has helped four toddlers - born with one of the most severe forms of childhood ...
Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...
15h
GlobalData on MSNPfizer shelves haemophilia gene therapy Beqvez amid low demandPfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.
13hon MSN
A Connecticut boy is among four children all born with severe childhood blindness who gained “life-changing improvements” to ...
15h
IFLScience on MSNInhalable Cystic Fibrosis Gene Therapy 24 Years In The Making Enters Clinical TrialsA new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...
The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.
Humans have appreciated the beauty of flowers for centuries. Yet, flowers aren't just aesthetically pleasing. They also play ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results